Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2002

View Archived Issues

Potential use of the HSPPC-96 vaccine in patients with metastatic renal cell carcinoma

Topical diltiazem in chronic anal fissures unresponsive to glyceryl trinitrate

Improvement in symptoms in autistic children treated with levetiracetam

Cardioprotective effects of JTV-519 and relationship to nitric oxide synthase

AC-7700 reduces tumor blood flow and inhibits tumor growth in rats

Anxiolytic actions of LY-354740 differ from diazepam in animal model

Four Pfizer patents describe novel PDE4 inhibitors

New 5-HT6 receptor modulators with potential in schizophrenia and other disorders

Vertex researchers identify new bacterial gyrase inhibitors

Novel inhibitors of HCV NS3 protease in BMS pipeline

Antiarrhythmic series covered by AstraZeneca patent

Subtype-selective NMDA NR2B antagonists recently presented by Roche

Taisho and Toyama sign contract of alliance for new sales and marketing company

Sangamo and Avigen collaborate for treatment of chronic pain

Phase I/II results for INS-37217 in rhegmatogenous retinal detachment

Genteric receives SBIR grant to evaluate DNA vaccines

Chugai becomes part of the Roche Group

Mode of action of LY-329332, a new vancomycin derivative

DNA-binding antibacterial agents a focus of research at Genelabs

HIV-1 nucleocapsid zinc finger inhibitors validated as selective antiviral agents

Humanized anti-VEGF antibody fragment proves effective in wet AMD

Igeneon licenses IGN-301 from Novartis

Avax signs distribution agreement with Ferrer for AC Vaccine technology

National Cancer Institute to study Combidex and Code 7228 in detection of lymph node disease

Aastrom and Stanford University collaborate on cell-based treatment for multiple myeloma

Viventia options novel immunotoxin from U. of Zurich

Positive clinical results for PT-141 in moderate to severe MED

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...